期刊文献+

前列腺癌内分泌治疗药Degarelix 被引量:2

下载PDF
导出
作者 刘一方 范鸣
出处 《药学进展》 CAS 2009年第10期473-475,共3页 Progress in Pharmaceutical Sciences
  • 相关文献

同被引文献23

  • 1Francois Ghiringhelli,Nicolas Isambert,Sylvain Ladoire.Degarelix as a new antiangiogenic agent for metastatic colon cancer?[J].World Journal of Gastroenterology,2013,19(5):769-772. 被引量:2
  • 2吴建辉,朱焰,孙祖越.治疗前列腺增生的国家一类新药——爱普列特[J].药学进展,2002,26(1):55-57. 被引量:19
  • 3吴晓明.盐酸坦洛新的新剂型上市[J].药学进展,2005,29(1). 被引量:1
  • 4Parsons JK,Kashefi C.Physical activity,benign prostatic hyperplasia,and lower urinary tract symptoms[J].Eur Urol,2008,53(6):1228-1235.
  • 5Safarinejad MR.Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older[J] ,Int Urol Nephrol,2008,40(4):921-931.
  • 6Hayashi T,Sakai Y,Saito K,et al.A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia[J].Hinyokika Kiyo,2002,48(1):7-11.
  • 7Matsubara Y,Kanazawa T,Kojima Y,et al.Pharmacokinetics and disposition of silodosin(KMD-3213)[J].Yakugaku Zasshi,2006,126:237.
  • 8Roehrborn CG,Siami P,Barkin J,et al.The influence of baseline parameters on changes in international prostate symptom score with dutasteride,tamsulosin,and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate:2-year data from the combat study[J].Eur Urol,2009,55(2):461-471.
  • 9Rick FG,Schally AV,Block NL,et al.LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia[J].Prostate,2010:Epub ahead of print.
  • 10Muthyala R,Ju Y,Sheng S,et al.Equol,a natural estrogenic metabolite from soy isoflavones:convenient preparation and resolution of R-and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta[J].Bioorg Med Chem,2004,12(6):1559-1567.

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部